Study guide
14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
Key Takeaways Explain This Topic AI
FDA-approved anti-obesity pharmacotherapy is indicated as an adjunct to lifestyle modification in adults with a BMI ≥30.0 kg/m², or a BMI ≥27.0 kg/m² in the presence of at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, CAD, or obstructive sleep apnea).
In the landmark SELECT cardiovascular outcomes trial, once-weekly subcutaneous semaglutide 2.4 mg (Wegovy) reduced major adverse cardiovascular events (3-point MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% (HR 0.80, 95% CI 0.72–0.90) in 17,604 overweight/obese patients with established CVD and without diabetes over 3.3 years.
Dual GIP and GLP-1 receptor agonist tirzepatide (Zepbound) elicits substantial, dose-dependent mean weight loss of 20% to 25% of baseline body mass, surpassing mono-incretin therapies and demonstrating significant improvements in blood pressure, glycemic biomarkers, and obstructive sleep apnea severity.
Centrally acting sympathomimetics (such as phentermine alone or combined with topiramate) stimulate central and peripheral norepinephrine release, inducing resting tachycardia, elevated blood pressure, and increased rate-pressure product, making them contraindicated in patients with coronary artery disease, uncontrolled hypertension, history of stroke, or cardiac arrhythmias.
Metabolic and bariatric surgery (MBS; sleeve gastrectomy and Roux-en-Y gastric bypass) is indicated for BMI ≥35 kg/m² or BMI 30.0–34.9 kg/m² with metabolic comorbidities; post-bariatric cardiac rehabilitation requires specialized surveillance for early/late dumping syndrome, rapid dehydration, and lean tissue preservation through progressive resistance exercise.
Last updated: September 2026
14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
Note
Clinical Competency Core : The management of obesity has undergone a transformative paradigm shift from purely behavioral advice to biological and metabolic disease intervention. Incretin-based pharmacotherapies (GLP-1 receptor agonists and dual GIP/GLP-1 agonists) and metabolic/bariatric surgery (MBS) achieve unprecedented weight loss and robust reductions in major adverse cardiovascular events (MACE). Cardiac rehabilitation professionals must master the clinical trial evidence, hemodynamic impacts, drug-exercise interactions, and post-surgical precautions (e.g., dumping syndrome, rapid dehydration, lean muscle wasting) associated with these advanced therapies.
Obesity is a relapsing, neurochemical, and hormonal disorder driven by central dysregulation of energy homeostasis. While comprehensive lifestyle modification remains the foundational bedrock of cardiac rehabilitation, biological counter-regulations frequently limit long-term behavioral weight reduction to 5% to 7%. For patients with substantial residual cardiovascular risk, clinical guidelines mandate considering advanced pharmacotherapeutic and surgical metabolic therapies.
Clinical Indications for Anti-Obesity Pharmacotherapy
The U.S. Food and Drug Administration (FDA) and clinical practice guidelines from the Endocrine Society, AHA/ACC, and AACVPR establish standard criteria for initiating prescription anti-obesity pharmacotherapy as an adjunct to a reduced-calorie diet and increased physical activity:
BMI ≥ 30.0 kg/m² (generalized obesity), OR
BMI ≥ 27.0 kg/m² (overweight) in the presence of at least one weight-related comorbid condition:
- Hypertension
- Dyslipidemia (hypertriglyceridemia, low HDL-C, atherogenic dyslipidemia)
- Type 2 Diabetes Mellitus or Prediabetes
- Established Atherosclerotic Cardiovascular Disease (CAD, prior MI, prior PCI/CABG)
- Obstructive Sleep Apnea (OSA)
Pharmacotherapy represents a chronic disease treatment model; discontinuing medications typically triggers biological rebound, with regain of up to two-thirds of lost weight within one year.
Incretin-Based Anti-Obesity Medications: GLP-1 and Dual GIP/GLP-1 Agonists
Incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—are peptide hormones secreted by enteroendocrine L-cells and K-cells of the gastrointestinal tract in response to nutrient ingestion. Synthetic incretin receptor agonists leverage these evolutionary pathways to modulate appetite, glucose regulation, and cardiovascular physiology.
Loading diagram...
1. Semaglutide 2.4 mg Weekly (Wegovy)
Semaglutide is a long-acting human GLP-1 receptor agonist with 94% structural homology to native GLP-1, engineered with an albumin-binding fatty acid diacid chain that extends its half-life to approximately 1 week.
Weight Loss Efficacy (STEP Program) : In the landmark STEP-1 trial (Semaglutide Treatment Effect in People with Obesity), subcutaneous semaglutide 2.4 mg once weekly combined with lifestyle intervention produced an average 14.9% mean reduction in body weight at 68 weeks (compared to 2.4% with placebo).
The SELECT Cardiovascular Outcomes Trial (NEJM 2023) : The SELECT trial was a paradigm-defining multi-center, double-blind, randomized controlled trial that enrolled 17,604 patients aged ≥45 years with established cardiovascular disease (prior MI, prior ischemic stroke, or symptomatic peripheral arterial disease) and a BMI ≥27 kg/m² who had NO history of diabetes mellitus . Over a mean follow-up of 39.8 months (3.3 years):
Primary Outcome : Once-weekly subcutaneous semaglutide 2.4 mg achieved a statistically significant 20% relative risk reduction in 3-point MACE (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; hazard ratio 0.80, 95% CI 0.72–0.90, p < 0.001 ).
Secondary Endpoints : Significant reductions in cardiovascular death (HR 0.85), heart failure composite events (HR 0.82), and all-cause mortality (HR 0.81).
Clinical Significance : SELECT proved unequivocally that targeted weight reduction via incretin therapy confers direct ischemic cardiovascular protection in secondary prevention patients without diabetes, moving anti-obesity pharmacotherapy directly into standard secondary prevention alongside statins, antiplatelet therapy, and beta-blockers.
2. Tirzepatide (Zepbound)
Tirzepatide is a novel synthetic unimolecular dual GIP and GLP-1 receptor agonist administered subcutaneously once weekly.
Weight Loss Efficacy (SURMOUNT Program) : In the SURMOUNT-1 trial, tirzepatide at doses of 5 mg, 10 mg, and 15 mg once weekly produced dose-dependent mean weight reductions of 15.0%, 19.5%, and 20.9% (up to 25.3% in on-treatment analysis) at 72 weeks in adults with obesity without diabetes.
Metabolic & Cardiovascular Effects : Tirzepatide produces profound reductions in visceral and intra-hepatic fat, lowers systolic blood pressure by an average of 6 to 8 mmHg, improves lipid subfractions, and significantly improves apnea-hypopnea index (AHI) scores in obstructive sleep apnea.
3. Liraglutide 3.0 mg Daily (Saxenda)
A daily subcutaneous GLP-1 receptor agonist evaluated in the SCALE trial program, producing an average 8.0% weight loss. In the LEADER trial (at 1.8 mg daily in diabetic patients), liraglutide demonstrated a 13% reduction in 3-point MACE. Due to once-daily dosing and lower efficacy compared to weekly semaglutide and tirzepatide, it is primarily utilized as a second-line incretin option.
Comparison of Anti-Obesity Pharmacotherapies & Cardiac Rehabilitation Considerations
Medication Class & Mechanism Mean Weight Loss Cardiovascular Impact & Regulatory Status Specific Cardiac Rehabilitation Considerations
Semaglutide 2.4 mg (Wegovy) GLP-1 Receptor Agonist (Weekly SQ) ~15% FDA-approved for secondary CV risk reduction in established CVD (SELECT trial: 20% MACE reduction). Resting heart rate increases by 2–4 bpm due to direct sinoatrial GLP-1 receptor stimulation. Gastrointestinal side effects (nausea, vomiting, delayed gastric emptying); avoid large pre-exercise meals. Prescribe resistance training to prevent lean muscle loss.
Tirzepatide (Zepbound) Dual GIP / GLP-1 Receptor Agonist (Weekly SQ) ~20% – 25% Robust BP reduction (6–8 mmHg); reduces systemic inflammation and liver fat. CV outcomes trial (SURPASS-CVOT) ongoing. Unprecedented weight loss rate; high risk of skeletal muscle mass loss (up to 25%–30% of total mass lost) without progressive resistance training and adequate protein intake (1.2–1.6 g/kg/day). Monitor for GI intolerance and hypovolemia.
Phentermine (Adipex-P, Lomaira) Noradrenergic Sympathomimetic Amine (Oral Daily) ~3% – 5% CONTRAINDICATED in established CAD , uncontrolled HTN, stroke, arrhythmias, or hyperthyroidism. Short-term use only (<12 weeks). Stimulates central/peripheral norepinephrine release. Causes resting tachycardia, palpitations, and blood pressure elevations . Increases rate-pressure product (double product) and myocardial oxygen demand (MVO2).
Phentermine / Topiramate ER (Qsymia) Sympathomimetic + GABA Receptor Agonist / Neuro-stabilizer ~8% – 10% CONTRAINDICATED in CAD and unstable cardiovascular disease. Requires REMS program for teratogenicity. Increases resting heart rate by 2–5 bpm; can provoke exertional arrhythmias or ischemia in compromised coronary beds. Carbonic anhydrase inhibition (topiramate) may cause metabolic acidosis and hypohidrosis.
Naltrexone / Bupropion SR (Contrave) Opioid Antagonist + Dopamine/Norepinephrine Reuptake Inhibitor ~5% – 6% Caution in CAD and HTN . Can raise resting BP (1–3 mmHg) and HR. Black box warning for suicidal ideation. Bupropion inhibits dopamine/norepinephrine reuptake; can elevate blood pressure and lower seizure threshold. Contraindicated with chronic opioid use (blocks analgesics during cardiac procedures).
Orlistat (Xenical, Alli) Pancreatic & Gastric Lipase Inhibitor ~5% Neutral CV hemodynamic impact. Poor patient compliance due to GI adverse effects. Inhibits dietary fat absorption by 30%. Causes severe gastrointestinal distress (steatorrhea, fecal urgency, flatulence). Impairs absorption of fat-soluble vitamins (A, D, E, K); can alter warfarin anticoagulation (vitamin K depletion).
Clinical Warning: Preserving Lean Muscle Mass During Incretin Therapy
In both the STEP and SURMOUNT clinical trials, body composition substudies demonstrated that 25% to 40% of total weight lost during rapid incretin-mediated weight reduction derived from lean skeletal muscle mass (fat-free mass) . In older cardiac rehabilitation patients, losing lean mass exacerbates sarcopenia, impairs balance, reduces bone mineral density, and compromises long-term functional autonomy.
Cardiac Rehabilitation Intervention : Clinicians must ensure that any patient on incretin therapy performs progressive resistance training at least 2 to 3 days per week (1–3 sets of 10–15 repetitions, RPE 11–14 on Borg 6–20 scale) and consumes targeted dietary protein ( 1.2 to 1.6 g/kg of ideal body weight per day ) to stimulate muscle protein synthesis.
Metabolic and Bariatric Surgery (MBS)
Metabolic and bariatric surgery represents the most potent and durable intervention for severe obesity and associated cardiometabolic disease.
Updated Indications (2022 ASMBS / IFSO Guidelines)
In 2022, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) updated the historical 1991 NIH criteria:
BMI ≥ 35.0 kg/m² regardless of the presence, absence, or severity of comorbid conditions.
BMI 30.0 to 34.9 kg/m² in patients with metabolic disease, including type 2 diabetes mellitus refractory to lifestyle and medical therapy, severe hypertension, obstructive sleep apnea, or non-alcoholic steatohepatitis (NASH).
Asian Populations : Thresholds are adjusted downward: BMI ≥ 27.5 kg/m² qualifies for metabolic surgery.
Primary Surgical Procedures
Sleeve Gastrectomy (SG) : The surgeon transects and removes approximately 75% to 80% of the greater curvature of the stomach, creating a narrow, tubular gastric sleeve along the lesser curvature. It operates primarily as a restrictive procedure and markedly suppresses circulating ghrelin by resecting the gastric fundus.
Roux-en-Y Gastric Bypass (RYGB) : The surgeon creates a small (<30 mL) proximal gastric pouch, which is directly anastomosed to the mid-jejunum via a Roux limb (gastrojejunostomy). The excluded gastric remnant, duodenum, and proximal jejunum form the biliopancreatic limb, which is reconnected distally. RYGB provides both restrictive and mild malabsorptive mechanisms, triggering profound, rapid postprandial secretion of endogenous GLP-1, PYY, and oxyntomodulin.
Long-Term Cardiovascular Outcomes
Landmark prospective long-term trials—including the Swedish Obese Subjects (SOS) study and the STAMPEDE trial —demonstrate that bariatric surgery achieves:
Long-term sustained weight loss of 25% to 35% at 10 to 20 years.
Complete or partial remission of type 2 diabetes in 50% to 75% of patients.
A 30% to 50% relative reduction in long-term cardiovascular mortality , with dramatic decreases in fatal and nonfatal myocardial infarction, stroke, and new-onset heart failure.
Post-Bariatric Surgery Management in Cardiac Rehabilitation
When a post-bariatric surgery patient enters Phase II cardiac rehabilitation, the clinical team must implement specialized monitoring protocols:
1. Differentiating Early vs. Late Dumping Syndrome
Dumping syndrome is an acute, distressing physiological complication following gastric surgery (particularly RYGB):
- Feature Early Dumping Syndrome Late Dumping Syndrome
- Onset Timing 10 to 30 minutes postprandially 1 to 3 hours postprandially
Underlying Pathophysiology Rapid transit of hyperosmolar chyme (especially concentrated simple sugars) into the jejunum draws massive fluid from the intravascular space into the bowel lumen via osmotic pressure. Rapid gastric emptying causes rapid glucose absorption, triggering a massive, exaggerated pancreatic insulin surge that outlasts circulating glucose levels.
Clinical Signs & Symptoms Acute systemic hypovolemia and hypotension : diaphoresis, lightheadedness, facial flushing, palpitations, tachycardia (HR spikes >100 bpm), nausea, and explosive abdominal cramping/diarrhea. Reactive hyperinsulinemic hypoglycemia : neuroglycopenic symptoms including severe tremor, diaphoresis, dizziness, confusion, hunger, syncope, and visual disturbances during or following exercise.
Exercise Management in CR Discontinue exercise immediately; have the patient lie recumbent to restore venous return and blood pressure; provide oral rehydration. Check capillary blood glucose immediately; if <70 mg/dL (or symptomatic), treat with 15 g of fast-acting glucose, retest in 15 minutes ("Rule of 15").
Dietary Prevention Completely avoid concentrated sweets/simple sugars; separate fluids from solid meals by at least 30 minutes ; consume small, frequent meals high in complex fiber and protein. Avoid high-glycemic carbohydrates; combine complex carbohydrates with protein and healthy fats to blunt rapid glucose-insulin spikes.
2. Hydration Balance and Orthostasis
Because the anatomical gastric pouch or sleeve holds only 30 to 100 mL, post-bariatric patients cannot consume large fluid boluses. Inability to drink adequate water during or after aerobic exercise rapidly leads to dehydration, decreased intravascular volume, and exertional orthostatic hypotension . Clinicians must instruct patients to continuously sip water throughout the day (targeting 1.5 to 2.0 liters/day) while avoiding fluids 30 minutes before and after meals.
3. Micronutrient Surveillance
Malabsorptive procedures (RYGB) impair absorption of iron, vitamin B12, folate, calcium, and fat-soluble vitamins (A, D, E, K). In cardiac rehabilitation:
Iron and B12 Deficiencies : Provoke microcytic or macrocytic anemia, manifesting as unexplained exertional fatigue, disproportionate dyspnea, and tachycardia during exercise training.
Calcium & Vitamin D Deficiencies : Accelerate bone mineral loss, requiring avoidance of high-impact ballistic exercises.
4. Incisional Healing & Exercise Resumption
Aerobic Exercise : Low-impact walking can resume immediately post-hospital discharge.
Resistance Training : Upper-body and core resistance exercises must be deferred for 4 to 6 weeks post-laparoscopy (longer if open laparotomy) until cleared by the bariatric surgical team, preventing incisional hernia formation and protecting the healing abdominal fascia. Clinicians avoid Valsalva maneuvers and high intra-abdominal pressures.
Clinical Case Scenario: GLP-1 Therapy and Sarcopenia Prevention in Post-CABG Rehabilitation
Patient Presentation : A 58-year-old male with severe three-vessel CAD, hypertension, and Class II obesity (BMI 36.4 kg/m², baseline weight 115 kg / 253 lbs) enrolls in Phase II cardiac rehabilitation 6 weeks following CABG x3. His cardiologist started him on subcutaneous semaglutide 2.4 mg weekly 1 month ago. The patient reports having lost 5 kg (11 lbs) in 4 weeks, but states: "I feel terribly weak. My legs shake when I climb stairs, and I have zero appetite."
Clinical Evaluation & Findings :
Nutritional Intake : Patient is consuming barely 900 kcal/day with <35 g/day of protein due to persistent medication-induced nausea and early satiety.
Physical Assessment : Sternal incision is well-healed and stable without clicks or separation. Grip strength has decreased by 18% compared to pre-operative baseline. Resting heart rate is 84 bpm (elevated by 6 bpm from pre-CABG baseline on metoprolol succinate 50 mg daily).
Clinical Decision-Making & CR Care Plan :
Identify Incretin-Induced Sarcopenia Risk : The CR team recognizes that his rapid weight loss consists disproportionately of skeletal muscle catabolism driven by extreme caloric restriction (<1,000 kcal/day) and inadequate protein intake.
Nutritional Prescription : In collaboration with the CR registered dietitian, his daily protein target is established at 1.3 g/kg of ideal body weight (~95–105 g/day), utilizing easily digestible whey protein isolate shakes and divided small protein snacks taken throughout the day.
Medication Adjustment : The team coordinates with the prescribing cardiologist to temporarily step down the semaglutide dose to 1.0 mg weekly until gastrointestinal side effects resolve and adequate nutritional intake is re-established.
Structured Resistance Training : Having passed 6 weeks post-CABG with a stable sternum, the clinician initiates light resistance training (elastic bands and light dumbbells: seated chest press, seated row, leg press; 1 set of 12 repetitions at RPE 11) to stimulate myofibrillar protein synthesis and reverse skeletal muscle loss.